Skip to main content

Judd Wendell Moul, MD

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Office: 1573 White Zone, Duke South, Durham, NC 27710
Campus Mail: DUMC Box 3707 Med Ctr, Durham, NC 27710

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Education and Training

  • Fellowship, Urologic Oncology, Duke University, 1988 - 1989
  • Residency, Urology, Walter Reed Army Medical Center, 1983 - 1987
  • Residency, Surgery, Walter Reed Army Medical Center, 1982 - 1983
  • M.D., Thomas Jefferson University, 1982
  • B.S., Pennsylvania State University, 1979

Publications

Moul, J. W., S. J. Maygarden, J. L. Ware, J. L. Mohler, P. D. Maher, N. S. Schenkman, and C. K. Ho. “Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy..” J Urol 155, no. 3 (March 1996): 982–85.

Scholars@Duke

Douglas, T. H., W. F. McCarthy, D. G. McLeod, and J. W. Moul. “Patient selection for experimental adjuvant therapy after radical prostatectomy..” Urology, February 1996. https://doi.org/10.1016/S0090-4295(99)80436-1.

Full Text

Schwartz, B. F., R. Auman, S. J. Peretsman, J. W. Moul, G. E. Deshon, J. Hernandez, R. A. Rozanski, and J. B. Thrasher. “Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis..” J Surg Oncol 61, no. 2 (February 1996): 131–33. https://doi.org/10.1002/(SICI)1096-9098(199602)61:2<131::AID-JSO7>3.0.CO;2-D.

Full Text

Morgan, T. O., D. G. McLeod, E. S. Leifer, J. W. Moul, and G. P. Murphy. “Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA..” Prostate Suppl 7 (1996): 58–63.

Scholars@Duke

Heidenreich, A., R. Vorreuther, B. Krug, J. W. Moul, and U. H. Engelmann. “Renal milk of calcium: contraindication to extracorporeal shockwave lithotripsy..” Tech Urol 2, no. 2 (1996): 102–7.

Scholars@Duke

Srivastava, S., D. Katayose, Y. A. Tong, C. R. Craig, D. G. McLeod, J. W. Moul, K. H. Cowan, and P. Seth. “Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation..” Urology 46, no. 6 (December 1995): 843–48. https://doi.org/10.1016/S0090-4295(99)80355-0.

Full Text

Bauer, J. J., I. A. Sesterhenn, K. F. Mostofi, D. G. McLeod, S. Srivastava, and J. W. Moul. “p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy..” Clin Cancer Res 1, no. 11 (November 1995): 1295–1300.

Scholars@Duke

Moul, J. W., I. A. Sesterhenn, R. R. Connelly, T. Douglas, S. Srivastava, F. K. Mostofi, and D. G. McLeod. “Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men..” Jama 274, no. 16 (October 25, 1995): 1277–81.

Scholars@Duke

Heidenberg, H. B., I. A. Sesterhenn, J. P. Gaddipati, C. M. Weghorst, G. S. Buzard, J. W. Moul, and S. Srivastava. “Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer..” J Urol 154, no. 2 Pt 1 (August 1995): 414–21. https://doi.org/10.1097/00005392-199508000-00024.

Full Text

Schenkman, N. S., I. A. Sesterhenn, L. Washington, Y. A. Tong, C. M. Weghorst, G. S. Buzard, S. Srivastava, and J. W. Moul. “Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors..” J Urol 154, no. 2 Pt 1 (August 1995): 617–21. https://doi.org/10.1097/00005392-199508000-00081.

Full Text

Pages